Record Date

July 31, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 35/26-27 Our Reference No. 35/26-27 Dear Sir/ Madam, Sub: Outcome of Board Meeting for the quarter ended June 30, 2026 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform that the Board at its meeting held today, i.e. July 31, 2026 has approved the following: A. Financial Results 1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026; and 2. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. B. Annual General Meeting (“AGM”) and Record Date 1. The 48th (Forty - Eighth) AGM of the members of the Company will be held on Friday, September 11, 2026, at 2:00 P.M. at Mumbai through video-conferencing / other audio- visual means; 2. The proceedings of the AGM shall be deemed to be conducted at the Corporate Office of the Company, i.e. at Glenmark House, B D Sawant Marg, Off Western Express Highway, Andheri (E), Mumbai 400 099; and 3. The record date for the purpose of determining the entitlement of dividend for the AGM to be held for the Financial Year ended March 31, 2026 shall be Monday, August 31, 2026. Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com C. Amendments to Policies The Board of Directors on the recommendation of respective Committees considered and approved the amendments/review of the following policies: a. Policy on Related Party Transactions and its Materiality b. Policy on Determination of Materiality for Disclosures c. Insider Trading Policy d. Dividend Distribution Policy e. Nomination and Remuneration Policy The revised policies shall be uploaded on the website of the Company. D. Reconstitution of Risk Management Committee The Board has approved the reconstitution of the Risk Management Committee with effect from August 01, 2026, where Ms. Patricia Andrews has been appointed as the Chairperson and Mr. Glenn Saldanha, Mr. Anurag Mantri and Mr. Dipankar Bhattacharjee will be the Members of the Committee. The Board Meeting commenced at 04.00 p.m. and concluded at 06:20 p.m. This intimation will also be uploaded on the Company’s website at www.glenmarkpharma.com and the extract of the aforesaid results would be published in the newspapers in accordance with the Listing Regulations. You are requested to take the same on records. Thanking You. Yours faithfully, Rashmi Khandelwal Company Secretary & Compliance Officer ACS – 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com qlenma~k A new way for a new world Glenmark Pharmaceuticals Limited Statement of Unaudited finauclal reaults for the quarter ended 30 Juae 2026 (All amounts in million of Indian Rupees unless otherwise stated) Standalone Particulars Quarter ended Quarter ended Quarter ended Yeu ended 30/06/2026 31/03/2026 30/06/2025 31/03/2026 (Ua.audJ.tedJ (Refer note 9) (Unaudited) (Audited) I Revenue from operations (a) Net sales 23,425.26 22,075.64 21,788.96 79,342.23 (b) Other operating income 924.67 (609.88) 2,160.32 5,058.76 Tota1 revenue from operations 24,349.93 21,465.76 23,949.28 84,400.99 II Other income 1,154.11 3,078.76 693.35 7,720.23 III Total income ( I + II ) 25,504.04 24,544.52 24,642.63 92,121.22 IV Expenses (a) Cost of materials consumed 6,279.86 7,209.20 6,772.40 27,755.75 (b) Purchases of stock-in-trade 1,414.36 1,135.01 993.25 4,087.95 (c} Changes in inventories of finished goods, work-in-progress and stock-in-trade 491.60 (9.29) (584.10) (1,054.15) (d) Employee benefits expense 4,540.81 4,613.45 4,084.43 17,904.10 (e) Finance costs 232.45 179.12 154.58 787.45 (f) Depreciation, amortisation and impairment expense 623.17 601.33 576.39 2,358.89 (g) Other expenses 5,490.77 8,202.08 5,401.71 24,933.36 Total expenses (IV) 19,073.02 21,930.90 17,398.66 76,773.35 V Profit/ (loss) before exceptional items and tax ( III -IV ) 6,431.02 2,613.62 7,243.97 15,347.87 VI Exceptional items (gain)/ loss (Refer note 5) (2,230.00) 3,687.59 3,232.32 18,008.58 Vil Profit/ (loss) before tax (V • VI) 8,661.02 (1,073.97) 4:011.65 (2,660.71) VIII Tax expense : Current tax 1,128.41 701.72 Deferred tax 176.24 (334.95) 7.67 (652.72) IX Profit/ (loss) after tax for the period / year ( VII • VIII ) 7,356.37 (739.02) 3,302.26 (2,007.99) X Profit/ (loss) for the period / year attributable to: -Non-controlling interests - -Owners of the Company 7,356.37 (739.02) 3,302.26 (2,007.99) XI Other comprehensive income / (loss) A (i) Items that will not be reclassified to profit or loss 8.10 (10.51) (8.20) (159.85) (ii) Income tax relating to items that will not be reclassified to profit or loss (2.04) (26.95) 2.86 (9.71) B (i) Items that will be reclassified to profit or loss (ii) Income ~ax relating to items that will be reclassified to profit or loss Total other comprehensive income/(loss) for the period/ year 6.06 (37.46) (5.34) (169.56) XII Total comprehensive income for the period/ year (lX+XI) 7,362.43 (776.48) 3,296.92 (2,177.55) XIII Total comprehensive income attributable to: -Non-controlling interests - - -Owners of the Company 7,362.43 (776.48) 3,296.92 (2,177.55) XIV Paid up Equity Share Capital, Equity Shares of Re. 1 /-each 282.20 282.20 282.20 282.20 xv Other equity (other than revaluation resetve) 2,41,221.04 XVI Earnings per share (EPS) (not annualised except for the year ended 31 March) Basic jin Rupees ) 26.07 (2.62) 11.70 (7.12) Diluted (in Rupees ) 26.06 (2.62) 11.70 (7.12) !If )r'<; , Glenrnark Pharmaceuticals Lirnited~J MUMBAI Glenmark House, B. D. Sawant Marg, An J~-'..(Easc), Mu;1.Y'fJO 099, India T: +91224018 9999 F: +91224018 998( <-~~ld,~"'~1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, "B,~, esai Road, Mumbai 400 026 E: complianceofficer@glenmarkp qtenma~k A new way for a new world Glenmark Pharmaceutical• Limited Statement of Unaudited financial reaults for the quarter ended 30 June 2026 (All amounts in million of Indian Rupees, unless otherwise stated) Consolidated Particulars Quarter ended Quarter ended Quarter ended Year ended Quarter ei:aded 31/03/2026 30/06/2023 31/03/2026 Quarter e:a.ded CRefer note 9J (Unaudited) 1,Aa.dlted) I Revenue from operations (a) Net sales 39,317.30 37,602.77 30,593.33 1,67,114.03 (b) Other operating income 867.53 103.09 2,051.07 2,711.08 Total revenue from operations 40,184.83 37,705.86 32,644.40 1,69,825.11 II Other income 657.64 1,890.83 264.42 4,606.19 III Total income ( I + II ) 40,842.47 39,596.69 32,908.82 1,74,431.30 IV Expenses (a) Cost of materials consumed 6,010.66 7,311.96 7,324.68 29,614.59 (b) Purchases of stock-in-trade 6,607.53 4,462.93 5,813.41 23,966.43 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (160.20) (52.09) (2,982.33) (6,106.39) {d) Employee benefits expense 9,346.95 8,874.41 7,627.54 35,778.53 (e) Finance costs .539.97 426.04 582.26 2,087.25 (f) Depreciation, amortisation and impairment expense 1,731.74 1,479.09 1,299.26 5,734.81 (g [Showing first 8,000 characters — download PDF for full document]